Most ankle sprain research is either false or clinically unimportant: A 30-year audit of Randomized Controlled Trials by Bleakley, C M et al.
1 
 
Most ankle sprain research is either false or clinically unimportant: A 30-year audit 1 
of Randomized Controlled Trials 2 
 3 
Bleakley CM PhD 1  4 
Matthews M PhD 2 5 
Smoliga JM PhD 3   6 
 7 
1School of Health Science, Ulster University, County Antrim, Northern Ireland 8 
2School of Sport, Ulster University, County Antrim, Northern Ireland 9 
3Department of Physical Therapy, Congdon School of Health Science, High Point 10 
University, North Carolina, USA 11 
 12 
Corresponding author 13 
Dr Chris Bleakley 14 
Room 1D117 15 
School of Health Science,  16 
Ulster University,  17 
County Antrim,  18 
Northern Ireland 19 
Tel: +442890366025 20 
c.bleakley@ulster.ac.uk 21 
 22 
 23 
2 
 
Abstract  24 
Lateral ankle sprain (LAS) is the most common musculoskeletal injury. Although clinical 25 
research in this field is growing, there is a broader concern that clinical trial outcomes are 26 
often false and fail to translate into patient benefits. The aim of this review was to audit 27 
30 years of experimental research related to LAS management (n=74 RCT) and to 28 
determine if reports of treatment effectiveness could be validated beyond statistical 29 
certainty. Seventy-seven percent of trials reported positive treatment effects but there 30 
was a high risk of false discovery. Most trials were unregistered and relied solely on 31 
statistical significance, or lack of statistical significance, rather than interpreting key 32 
measures of minimum clinical importance (eg. minimal detectable change, minimal 33 
clinically important difference). Future clinical trials must adopt higher standards of 34 
reporting and data interpretation. This includes consideration of the ethical responsibility 35 
to preregister their research; and interpretation of clinical outcomes beyond statistical 36 
significance.  37 
 38 
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 47 
Background 48 
Lateral ankle sprain (LAS) is the most prevalent musculoskeletal injury in physically active 49 
populations.1 Although often considered innocuous, LAS has the highest re-injury rate 50 
across all lower limb musculoskeletal injuries,2 and the annual costs associated with 51 
sports-related ankle sprain in the Netherlands is estimated at €187,200,000.3 LAS also 52 
occurs frequently in the general population, with large cohorts suffering chronic 53 
problems;4 indeed, 305-75%6 develop a clinical condition known as chronic ankle 54 
instability (CAI), characterized by recurrent injury and self-reported instability.5 The long-55 
term costs associated with LAS and CAI are significant7 8 and relate to lower quality of 56 
life,9 physically inactivity4 and an increased risk of post-traumatic ankle osteoarthritis.5 10-57 
12,13  58 
Randomized controlled trials (RCTs) are currently considered to be the gold standard 59 
methodology for determining treatment superiority.14 The first RCT involving acute LAS 60 
was published in 1972.15  The Physiotherapy Evidence Database (PEDro) now archives 61 
over 150 RCTs involving patients with LAS or CAI, and a 2017 meta-evaluation16 in this 62 
field included 46 systematic reviews. Having access to high volumes of experimental 63 
research should improve the quality of healthcare, but there is much concern that many 64 
clinical trial outcomes are either false17,18 or they fail to translate into clinical benefits for 65 
patients.19 False discovery in science (eg. erroneously claiming a treatment is effective) 66 
often occurs due to over reliance on frequentist reasoning and p-value thresholds;20 a 67 
problem further compounded by unplanned multiple testing, selected reporting, and 68 
confirmation bias.21  69 
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Recently we introduced a four-point checklist (FAIR), which aims to validate experimental 70 
research beyond statistical certainty.22 The checklist assesses the following criteria: 71 
False Positive Risk (FPR), which is ‘the probability of observing a statistically significant 72 
p-value and declaring that an effect is real, when it is not’.23 A priori registration, which 73 
is essential for controlling the ‘degrees of freedom’ researchers have during data analysis 74 
and reporting,21 thereby reducing the risk of false positive findings. Clinical Importance, 75 
whereby the magnitude of treatment effect is compared to relevant minimal detectable 76 
change (MDC) and minimal clinically important difference (MCID)24 data. And finally, 77 
Replication, which should underpin all scientific discovery.   78 
Evidence based health care relies on the production of valid experimental data that 79 
translates into clinical benefits. This review examines the validity of conclusions from 30 80 
years of clinical trials into one of the most common musculoskeletal injuries - LAS and 81 
CAI. Our primary objective was to examine the extent to which reports of treatment 82 
effectiveness in this field, could be validated beyond statistical certainty. The FAIR 83 
checklist22 was applied, with higher validity placed on trials presenting with: low false 84 
positive risk; pre-registration; treatment effect magnitudes which exceeded relevant MDC 85 
and MCID values; and the corroboration of treatment effectiveness through independent 86 
replication.  87 
 88 
Methods  89 
Trial selection 90 
Review methods aligned with PRISMA.25 Electronic searching was undertaken 91 
independently by two authors (CB, MM) on MEDLINE, and the Physiotherapy Evidence 92 
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Database (PEDro).26 27 In MEDLINE we undertook a broad search strategy based on 93 
MeSH terms (ankle AND randomized controlled trial) and we used the PEDro search 94 
interface to run three separate searches for clinical trials using the terms ‘ankle sprain’, 95 
‘chronic ankle instability’, and ‘CAI’. Citation tracking was also undertaken using a recent 96 
meta-evaluation.16 To be eligible for inclusion, trials must have met the following criteria: 97 
a randomized controlled design; participants with LAS and/or CAI managed with at least 98 
one conservative treatment intervention; assessment of at least one clinically relevant 99 
outcome measure (eg. pain, function, range of motion, strength, balance). Trials were 100 
excluded if they involved any surgical intervention. No restrictions were placed on injury 101 
severity, participant demographics or follow-up duration. We did not include RCTs using: 102 
>2 treatment arms, equivalency or non-inferiority trials, pilot trials or trials published prior 103 
to 1990. Any disagreements in trial selection were resolved through consensus with a 104 
third reviewer (JS).   105 
 106 
Data extraction and analysis 107 
PICO (population, intervention, comparison, outcome) characteristics were extracted 108 
from the full text of all eligible trials, in addition to aims and hypothesis, n participants, 109 
follow-up time points, and the total number of between-group statistical comparisons 110 
undertaken. Included trials were then classified as being either statistically significant or 111 
null. A statistically significant trial was defined as a trial having a p-value less than 0.05 in 112 
the trial results tab for any clinical outcome.28 We also calculated the proportion of 113 
between-group comparisons that resulted in statistically significant findings within each 114 
individual trial, and whether they were recorded in primary or secondary outcome 115 
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measures. When trials included multiple outcome measures but did not clearly specify a 116 
‘primary’ outcome, the primary outcome was determined by the authors based on the 117 
nature of the research question and the following definition of a primary outcome ‘a 118 
specific key measurement(s) or observation(s) used to measure the effect of experimental 119 
variables in a trial.’29  The FAIR checklist22 was applied as follows:  120 
 121 
False Positive Risk 122 
Calculation of FPR followed methods used in a previous research audit in this field.30 FPR 123 
calculation is a special case of Bayesian analysis. It allows the p-value to be 124 
supplemented by a single number that gives a much better idea of the strength of the 125 
evidence than a p-value alone.23 We calculated FPR for all trials reporting a statistically 126 
significant finding from their primary outcome. All FPR calculations were performed using 127 
the False Positive Risk Web Calculator (version 1.5) using the following data: the n of 128 
participants in each group; a relevant p-value; and the corresponding effect size (Hedges 129 
g).31 Further details of the analysis script and simulated examples of FPR calculations 130 
can be found in Colquhoun’s recent articles.20 23 If a trial reported a p-value threshold 131 
such as p<0.05, rather than an exact p-value, we assumed that the p-value was one 132 
decimal place below the threshold value (e.g. p<0.05 was inputted as 0.049). The 133 
calculation of FPR also requires an estimation of the prior probability that there is a real 134 
effect [P(H1)] for a given treatment. In all trials, we initially assumed that P(H1) was 0.5 – 135 
ie. treatment interventions had a 50:50 chance of a (positive) real effect before the 136 
experiment was done.18 20 In all cases FPR estimations were calculated using the p-137 
equals method, as our aim was to interpret a single p-value from a single experiment 138 
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(rather than trying to estimate the long term error rate).31 Descriptive statistics were used 139 
to determine the median FPR and the number (%) of statistically significant p-values 140 
associated with FPR less than 5%.  141 
 142 
A Priori trial registration 143 
We determined the number (%) of eligible trials reporting preregistration; defined as the 144 
trial protocol being publicly available within a trial registry (e.g.ClinicalTrials.gov) prior to 145 
the initiation of participant recruitment. In a secondary analysis, we used odds ratios 146 
(ORs) and 95% confidence intervals (95% CI) to determine whether the likelihood of 147 
reporting a statistically significant outcome was influenced by a priori trial registration.   148 
 149 
Clinical Importance   150 
Initially, we determined the number (%) of trials that referenced or reported MDC and/or 151 
MCID values within the full text manuscript. When enough data were available, we 152 
calculated the mean differences (MD) and 95% confidence intervals (CI) for each clinical 153 
outcome, where MD = mean experimental – mean control. MD (95% CI) data were then 154 
compared to corresponding MDC and MCID data. If a trial did not report MDC or MCID 155 
data for a particular outcome, we searched the literature for relevant figures and inputted 156 
them. MDC was set at confidence levels of 95% and considered to be ‘the amount of 157 
change that must be observed before it is considered above the bounds of measurement 158 
error’.32  MCID was considered to be ‘the smallest change that would be important to 159 
patients’, and could have been quantified by externally referenced (anchor) or internally 160 
referenced (distribution) methods.33   161 
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 162 
Replication  163 
PICO criteria were compared across trials. If possible, homogeneous trials were sub 164 
grouped and their trial effects (magnitude and direction) were compared to screen for 165 
successful replication.  166 
 167 
 168 
Results  169 
We screened 1098 titles and abstracts (937 from Medline and 161 from PEDro), with 169 170 
selected for full-text review. n=74 RCTs were eligible for inclusion (Supplemental data 1), 171 
with the remainder (n=95) excluded (>2 treatment arms (n=45); no clinical outcomes 172 
(n=9); non RCT (n=8); non English language (n=8) surgical intervention (n=7); non 173 
inferiority / equivalency (n=5), non-ankle sprain/CAI (n=5); other (n=8) (Figure 1). Trials 174 
included participants with either LAS (n=53 trials) or CAI (n=21 trials). In most trials, the 175 
primary intervention involved external supports (n=30), exercise intervention (n=18), 176 
pharmacotherapy (n=14) manual therapy or electro-physical agents (n=11). The mean 177 
sample size was n=85.1 (SD=96.8; range 13-522) and 50% (37/74) reported using a priori 178 
sample size calculation. Most sample size estimations included alpha (Type 1 error) and 179 
beta (Type 2 error) levels of 5% and 20% respectively, with the average effect size 180 
estimated at 0.7 (SD=0.45) a priori.  181 
Insert Figure 1 here. 182 
 183 
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Twenty-three percent (17/74) of RCTs were classed as null (no treatment effects 184 
reported). The remaining 77% (57/74) reported statistically significant findings from at 185 
least one outcome measure. We extracted an aggregate of 966 p-values relating to 186 
between-group statistical comparisons involving primary or secondary outcomes, of 187 
which 35.4% (342/966) were statistically significant (p<0.05) (Figure 2A). Most statistically 188 
significant findings were derived from secondary outcomes, with just 17% (58/342) 189 
derived from primary outcome measures (Figure 2B). Out of the 966 p-values reported in 190 
the literature, only 11 (1%) represented statistically significant findings in a primary 191 
outcome measure reported from a pre-registered trial (Figure 2C). (Supplemental data 2) 192 
Insert Figure 2 here 193 
 194 
False positive risk 195 
Enough data were available to calculate effect sizes and FPR in 68% of trials (39/57) 196 
reporting significant effects (p<0.05) in their primary outcome. FPR is summarized in 197 
Figure 3; the median FPR was 14% (range 0.6 to 100%) and 28% of trials (11/39) had 198 
FPR less than 5%. (also see Supplemental data 3) 199 
Insert Figure 3 200 
 201 
A Priori trial registration 202 
Only 19% (14/74) of trials were preregistered. The average number of between-group 203 
comparisons reported across registered and unregistered trials was similar [12.8 (SD 9.0) 204 
vs 13.3 (SD 10.9) respectively], however unregistered trials were more likely to report p-205 
values less than 0.05 (OR=1.7 Cis: 1.2 to 2.4; p=.004).  206 
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 207 
Clinical importance   208 
Of the 57 trials reporting statistical significance, only 9% (5/57) made any reference to 209 
either MDC or MCID values. In a further 16 trials, we were able to extract relevant MDC 210 
and/or MCID values extracted from the existing literature, for the following outcomes 211 
measures: Foot and ankle outcome measure (FAAM);34 35 Cumberland ankle instability 212 
tool (CAIT);36 Lower extremity functional scale (LEFS);37 isometric / isokinetic ankle 213 
strength;38 39 limb circumference / swelling;40 41 range of motion;38 42 postural control;27 214 
pain43. Effect magnitudes (MD) exceeded the respective MDC or MCID values in 12 and 215 
7 trials respectively. Effect magnitudes exceeded both MDC and MCID in just 3 trials (also 216 
see Supplemental data 3) 217 
 218 
Replication 219 
Figure 4 summarizes the number of trials meeting more than one of the FAIR criteria. 220 
Three trials were both pre-registered and reported a low FPR (<5%), and one of the pre-221 
registered trials also reported a clinically important effect. No trial met all the following 222 
conditions: preregistered; low false positive risk (<5%); clear evidence that the magnitude 223 
of treatment effect exceeded both MDC and MCID values. There were no instances when 224 
a positive treatment effect was independently replicated.  225 
Insert Figure 4 here 226 
 227 
Discussion 228 
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There is concern that a large proportion of scientific research is based on false positive, 229 
non-replicable conclusions.17 Strategies known to reduce the risk of false discovery 230 
include: mandatory trial registration;21 false positive risk calculation,20 and use of MDC 231 
and MCID values to determine if reported treatment magnitudes are clinically 232 
meaningful.22 24 There is a dearth of empirical meta-research investigating the credibility 233 
of research practices in SEM research. Recent audits have highlighted a high propensity 234 
for questionable research practices (eg. HARKing, cherry picking, p-hacking) in high 235 
impact SEM journals;44 and we have previously found a high risk of false positive claims 236 
in the sports physiotherapy literature.30 This is the first piece of meta-research using a 237 
saturation of RCTs from a single field of musculoskeletal medicine. n=74 trials met our 238 
inclusion criteria, with 77% reporting statistically significant findings from at least one 239 
outcome measure. However, in most trials, data interpretation was limited to all or nothing 240 
Null Hypothesis Significance Testing, and most positive conclusions could not be 241 
validated beyond statistical certainty.   242 
Only 19% of trials in the LAS/CAI research literature were preregistered. Trial registration 243 
is now required as a condition of ethical approval,45 and audits of clinical trials undertaken 244 
in other fields of medicine (cardiology, rheumatology, and gastroenterology), show better 245 
adherence to current guidelines.46 One of our key findings was that unregistered trials 246 
were 70% more likely to report statistical significance (OR=1.7 Cis: 1.2-2.4) compared to 247 
those that were registered a priori. Unregistered trials typically carry a higher risk of false 248 
discovery due to: significance seeking, selective reporting of outcomes,47 or HARKing 249 
(hypothesizing after the results are known).21 In contrast, preregistration helps to control 250 
the ‘degrees of freedom’ a researcher has during data analysis and reporting,21 reducing 251 
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such risks. A related finding was that out of the 342 statistically significant p-values 252 
(<0.05) reported across trials, only 11 were generated from primary outcomes within pre-253 
registered trials. Consequently, the vast majority of statistically significant findings within 254 
the LAS/CAI evidence base, are derived from secondary outcomes in unregistered trials, 255 
and should therefore be considered exploratory or hypothesis generating.21   256 
 257 
Measures of minimum clinical importance, (MDC and MCID) are increasingly recognized 258 
as important thresholds for evaluating the efficacy of an intervention. However, the 259 
reporting of clinical significance is poor in RCTs involving patients with LAS or CAI, with 260 
just 9% of trials, referring to MDC or MCID data. After extracting MDC and MCID for 261 
clinical outcomes relating to pain, function, instability, strength and swelling, we were able 262 
to examine clinical efficacy in 21 trials; however, the results were disappointing with 50% 263 
of trials recording treatment effects which could not be differentiated from measurement 264 
error. Furthermore, in most trials, the treatment effects did not exceed relevant MCID 265 
figures, and are therefore unlikely to be considered important by patients with LAS and 266 
CAI. An initial audit48 of interventional research in the sports medicine literature, found 267 
that MDC or MCID was considered in 53% and 40% of trials respectively. However, a 268 
much larger audit of orthopaedic literature, found that only 7.5% of clinical science articles 269 
made reference to MCID,24  270 
 271 
It is expected that musculoskeletal injuries are managed from an evidence-based 272 
perspective, whereby the best available evidence is integrated with patient preference, 273 
clinical expertise, and the clinical context. As RCTs represent the gold standard 274 
13 
 
methodology for determining treatment superiority, they have a considerable influence on 275 
the relevance of adopting an evidence-based framework when treating patients with LAS 276 
or CAI. Our results raise fundamental questions about the current value of evidence-277 
based practice in this field and clarify that future clinical trials must adopt higher standards 278 
of reporting and data interpretation. Interestingly, there is a lack of robust clinical 279 
interpretation in other fields of medicine,49 and continuing to rely solely on NHST, not only 280 
wastes research funding, but erodes credibility and slows down scientific progress.50 281 
Although NHST remains an important step for determining treatment effectiveness, it is 282 
most efficient in the context of long-run repeated testing.50 We support the idea that p-283 
values are supplemented with a formal estimation of the false positive risk18 31 which 284 
represents “the probability, in the light of the p-value that you observe, you declare that 285 
an effect is real, when in fact, it isn’t.”23 Although it is often assumed that the FPR is equal 286 
to the reported p-value, they are different constructs and often vary considerably. Indeed, 287 
our audits shows that the median FPR associated with statistically significantly findings 288 
(p<0.05) was 14% (range 0.6-100%), and only 27% of trials had a FPR lower than 5%. 289 
These figures suggest that statistical significance alone is not a solid foundation for 290 
determining treatment effect, particularly when it is based on binary thresholds (p<0.05).  291 
 292 
Limitations 293 
Higher validity was assumed under the following conditions: derived from registered trials; 294 
low false positive risk; treatment effects exceeding MDC and MCID values. This is not an 295 
exhaustive list and we did not fully consider false discoveries relating to multiple treatment 296 
arms, the analysis of multiple outcomes, or multiple analyses of the same outcome at 297 
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different times.51 We acknowledge although preregistration increases the transparency 298 
and validity of trial conclusions, it is not a cure-all for efficient and accurate dissemination. 299 
Audits of clinicaltrials.gov show that approximately 20% of registered trials disseminate 300 
their results within 1 year of completion,52 with others highlighting quite a high risk of 301 
discordance between the original registry data and the published data.53  302 
We must also consider that our FPR calculations were based on assumptions that the 303 
prior probability of effect was 50%, but it is likely that some trials were underpinned by 304 
more extreme hypotheses. In previous data simulations,28 we have shown that a positive 305 
conclusion from an optimistic research question (i.e. a higher prior probability) is likely to 306 
be correct; whereas an unlikely hypotheses (where researchers are driven by pursuit of 307 
novelty) will have a much higher risk of false-positive reporting. Alternatives to FPR have 308 
been discussed by Colquhoun.23 Perhaps the most clinically intuitive option is use of a 309 
reverse Bayesian approach,54 where the observed p-value is used to calculate the prior 310 
probability required to achieve a specific or minimal false positive risk (eg. 5%). This then 311 
allows the researcher to determine whether the calculated prior is plausible or not.30 312 
Finally, many latent constructs  influence false discovery; this includes a scientific culture 313 
which places most value on statistically significant findings or novel discoveries.21  314 
 315 
Conclusion  316 
There is a high risk of false positive discovery in a core field of musculoskeletal research. 317 
A key concern is that most of the research in this field remains unregistered, and relies 318 
solely on statistical significance, or lack of statistical significance, rather than interpreting 319 
the magnitude of change. Researchers must consider the ethical responsibility to 320 
15 
 
preregister their research; and their interpretation of clinical outcomes must evolve 321 
beyond statistical significance.  322 
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Figure 1  474 
Flow diagram summarizing trial selection 475 
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Figure 2  483 
Area plots subgrouping p-values (n=966) by: level of significance (A), primary outcomes 484 
(B) and pre-registration (C)  485 
 486 
  487 
Figure 2 footnote 488 
Each square represents ~10 p-values generated from between-group comparisons.  489 
White squares = No statistical significance (p>0.05)  490 
Shaded squares represent:  491 
A). Statistically significant – primary or secondary outcomes 492 
B). Statistically significant - primary outcomes only, any trial 493 
C). Statistically significant - primary outcomes, pre-registered trials only  494 
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Figure 3 505 
Violin plot summarizing False Positive Risk in trials reporting significant (p<0.05) effects 506 
in their primary outcome 507 
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Figure 4  517 
Venn diagram illustrating N trials meeting one than one FAIR criteria 518 
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